Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Summary

A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.

Timeline

Start

2026-02-23

Primary completion

2027-04-30

Completion

2027-06-30

Drugs

Indications